VistaGen Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of VistaGen Therapeutics generated cash of -$25,813,000, which is more than the previous year. Cash used in financing activities reached the amount of $128,401,999 last year. Net change in cash is therefore $102,528,000.
Cash Flow
| 2015 | -2.76M | 0 | 2.83M |
|---|---|---|---|
| 2016 | -4.80M | -26.3K | 5.19M |
| 2017 | -7.26M | -239.1K | 9.99M |
| 2018 | -9.05M | -1.6K | 16.51M |
| 2019 | -14.52M | -174K | 17.42M |
| 2020 | -15.75M | 0 | 4.01M |
| 2021 | -12.07M | -275.4K | 114.10M |
| 2022 | -45.25M | -200.4K | 10.48M |
| 2023 | -49.71M | -740.3K | -1.04M |
| 2024 | -25.81M | -61K | 128.40M |
VTGN Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 16.63M | 68.13M | 103.10M | 1.35M | 13.10M | 10.37M | 2.92M | 428.5K | 70K | 0 |
Operating activities | ||||||||||
Net income | -29.36M | -59.24M | -47.76M | -17.93M | -20.77M | -24.58M | -14.34M | -10.25M | -47.22M | -13.88M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 568K | 509.8K | 711.1K | 117.6K | 103.1K | 91.2K | 80.7K | 54.9K | 53.5K | 59.1K |
Stock-based compensation expense | 2.18M | 3.33M | 3.48M | 2.30M | 3.82M | 3.44M | 2.34M | 851.3K | 4.04M | 2.46M |
| Deferred income tax benefit | 2.18M | 3.33M | 3.48M | 2.30M | 3.82M | 3.44M | 2.34M | 851.3K | 4.04M | 2.46M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | -40.6K | 300K | -300K | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | -51M | 390.7M | -20.77M | 0 | 0 | 0 | 0 |
Accounts payable | 522K | -932.8K | 1.68B | 51M | -390.7M | 22.7M | 135M | -451.7M | -547.2M | 2.02B |
Cash generated by operating activities | -25.81M | -49.71M | -45.25M | -12.07M | -15.75M | -14.52M | -9.05M | -7.26M | -4.80M | -2.76M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -61K | -212K | -200.4K | -275.4K | 0 | -174K | -1.6K | -239.1K | -26.3K | 0 |
Acquisitions Net | 0 | -528.3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -61K | -740.3K | -200.4K | -275.4K | 0 | -174K | -1.6K | -239.1K | -26.3K | 0 |
Financing activities | ||||||||||
Common Stock Issued | 129.37M | -6.4K | 4.43M | 114.48M | 4.30M | 17.04M | 16.72M | 9.89M | 280K | 3.14M |
Payments for dividends | 0 | 0 | -945.1M | 0 | 0 | -1.13B | 0 | -1.25B | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -985K | 0 | -3K | -3.3K | -3K | -2.7K | -205.4K | -1.3K | -112.5K | -307.7K |
Cash used in financing activities | 128.40M | -1.04M | 10.48M | 114.10M | 4.01M | 17.42M | 16.51M | 9.99M | 5.19M | 2.83M |
Net Change In Cash | 102.52M | -51.49M | -34.97M | 101.75M | -11.74M | 2.72M | 7.45M | 2.49M | 358.5K | 70K |
Cash at end of period | 119.16M | 16.63M | 68.13M | 103.10M | 1.35M | 13.10M | 10.37M | 2.92M | 428.5K | 70K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |